TOP TEN perturbations for 38465_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38465_at
Selected probe(set): 202336_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38465_at (202336_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Relative Expression (log2-ratio):-8.5542345Number of Samples:2 / 2
| Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
| Control | CNS cancer study 1 (PDX; ependymoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted). |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):-7.6613007Number of Samples:2 / 3
| Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
| Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |
Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample
Relative Expression (log2-ratio):4.0794315Number of Samples:7 / 3
| Experimental | Langerhans cell histiocytosis study 1 |
| Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
| Control | normal myeloid dendritic cell sample |
| Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):-3.9636583Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-3.9304733Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):-3.9131613Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):-3.7816944Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal T-cell sample |
| MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
dengue fever study 10 (DF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):3.7106028Number of Samples:3 / 5
| Experimental | dengue fever study 10 (DF) |
| Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. | |
| Control | normal naive CD8 T cell sample |
| Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.6924238Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.587636Number of Samples:2 / 22
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted). |